BRPI0514310A - 8-aminoalcóxi-xantinas substituìdas, método para a produção das mesmas e seu uso como medicamentos - Google Patents

8-aminoalcóxi-xantinas substituìdas, método para a produção das mesmas e seu uso como medicamentos

Info

Publication number
BRPI0514310A
BRPI0514310A BRPI0514310-1A BRPI0514310A BRPI0514310A BR PI0514310 A BRPI0514310 A BR PI0514310A BR PI0514310 A BRPI0514310 A BR PI0514310A BR PI0514310 A BRPI0514310 A BR PI0514310A
Authority
BR
Brazil
Prior art keywords
substituted
production
aminoalkoxy
xanthines
medicines
Prior art date
Application number
BRPI0514310-1A
Other languages
English (en)
Inventor
Karl Schoenafinger
Gerhard Jaehne
Elisabeth Defossa
Christian Buning
Georg Tschank
Ulrich Werner
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of BRPI0514310A publication Critical patent/BRPI0514310A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

8-AMINOALCóXI-XANTINAS SUBSTITUìDAS, MéTODO PARA A PRODUçãO DAS MESMAS E SEU USO COMO MEDICAMENTOS A presente invenção refere-se a 8-aminoalcóxi-xantinas substituídas e a sais fisiologicamente compatíveis e derivados fisiologicamente funcionais das mesmas. A presente invenção também refere-se a compostos de fórmula I, em que os radicais têm os significados acima mencionados, adicionalmente ao sais fisiologicamente compatíveis dos mesmos, Os compostos são adequados, por exemplo, como medicamentos para a prevenção e tratamento de diabetes do tipo 2.
BRPI0514310-1A 2004-08-14 2005-07-30 8-aminoalcóxi-xantinas substituìdas, método para a produção das mesmas e seu uso como medicamentos BRPI0514310A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004039507A DE102004039507A1 (de) 2004-08-14 2004-08-14 Substituierte 8-Aminoalkoxi-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PCT/EP2005/008283 WO2006018117A1 (de) 2004-08-14 2005-07-30 Substituierte 8-aminoalkoxi-xanthine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel

Publications (1)

Publication Number Publication Date
BRPI0514310A true BRPI0514310A (pt) 2008-06-10

Family

ID=35478703

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514310-1A BRPI0514310A (pt) 2004-08-14 2005-07-30 8-aminoalcóxi-xantinas substituìdas, método para a produção das mesmas e seu uso como medicamentos

Country Status (10)

Country Link
US (1) US7879864B2 (pt)
EP (1) EP1778690B1 (pt)
JP (1) JP2008509893A (pt)
AU (1) AU2005274494A1 (pt)
BR (1) BRPI0514310A (pt)
CA (1) CA2576561A1 (pt)
DE (1) DE102004039507A1 (pt)
IL (1) IL181012A0 (pt)
MX (1) MX2007001082A (pt)
WO (1) WO2006018117A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004037554A1 (de) * 2004-08-03 2006-03-16 Sanofi-Aventis Deutschland Gmbh Substituierte 8-Aminoalkylthio-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE602006017712D1 (de) 2005-08-24 2010-12-02 Banyu Pharma Co Ltd Phenylpyridonderivat
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2911655A1 (en) 2012-10-24 2015-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Tpl2 kinase inhibitors for preventing or treating diabetes and for promoting -cell survival
WO2014193528A1 (en) * 2013-04-29 2014-12-04 Anovel Pharmaceuticals, Llc Amorphous dosage forms and methods
ES2805743T3 (es) 2015-03-24 2021-02-15 Inst Nat Sante Rech Med Método y composición farmacéutica para uso en el tratamiento de la diabetes

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2688618A (en) * 1952-01-03 1954-09-07 Bristol Lab Inc Basic caffeine derivatives
DE1005517B (de) * 1955-12-30 1957-04-04 Cassella Farbwerke Mainkur Ag Verfahren zur Herstellung neuer quecksilberhaltiger Xanthinverbindungen
DE3232883A1 (de) * 1982-09-02 1984-03-08 Josef Dipl.-Chem. Dr.Rer.Nat. Klosa Neue salze von basischen coffein-8-aethern und ihre anwendung in pharmazeutischen praeparaten
EP0430300A3 (en) * 1989-12-01 1992-03-25 Takeda Chemical Industries, Ltd. Xanthine derivatives, their production and use
GB9020959D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
US5290801A (en) 1992-05-29 1994-03-01 The Du Pont Merck Pharmaceutical Company Benzimidazoles for the treatment of atherosclerosis
BR9810508A (pt) 1997-07-03 2000-09-05 Du Pont Pharm Co Composto, composição farmacêutica e método de tratamento de uma desordem
EP1173438A1 (en) 1999-04-16 2002-01-23 Novo Nordisk A/S Substituted imidazoles, their preparation and use
PT1368349E (pt) 2001-02-24 2007-04-30 Boehringer Ingelheim Pharma Derivados de xantina, sua preparação e sua utilização como medicamento
WO2004048379A1 (ja) * 2002-11-01 2004-06-10 Sumitomo Pharmaceuticals Co., Ltd. キサンチン化合物
DE102004037554A1 (de) * 2004-08-03 2006-03-16 Sanofi-Aventis Deutschland Gmbh Substituierte 8-Aminoalkylthio-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2007065595A2 (en) 2005-12-07 2007-06-14 Ucb Pharma, S.A. Xanthine derivatives, processes for preparing them and their uses
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms

Also Published As

Publication number Publication date
AU2005274494A1 (en) 2006-02-23
CA2576561A1 (en) 2006-02-23
EP1778690B1 (de) 2012-08-22
EP1778690A1 (de) 2007-05-02
IL181012A0 (en) 2007-07-04
DE102004039507A1 (de) 2006-03-02
WO2006018117A1 (de) 2006-02-23
JP2008509893A (ja) 2008-04-03
US20070299090A1 (en) 2007-12-27
MX2007001082A (es) 2007-04-19
US7879864B2 (en) 2011-02-01

Similar Documents

Publication Publication Date Title
BRPI0514310A (pt) 8-aminoalcóxi-xantinas substituìdas, método para a produção das mesmas e seu uso como medicamentos
BRPI0513086A (pt) 8-pirrolidinoxantinas bicìclicas substituìdas, processo para a produção das mesmas e seu uso como medicamentos
BRPI0507309A (pt) derivados de ácido 7-fenilamino-4quinolon-3-carboxìlico, processos para produção e seu uso como medicamento
BR0312513A (pt) Derivados de glicosìdeo de tiofeno, processos para a produção dos mesmos, medicamentos que contêm esses compostos e uso dos mesmos
BR0317283A (pt) Derivados heterocìclicos de flúor-glicosìdeo, medicamentos contendo estes compostos e seu uso
BRPI0610850A2 (pt) derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados
BRPI0512075A (pt) composto, processo para a preparação do mesmo, composição farmacêutica, uso de um composto, e, métodos para a produção de um efeito inibidor de b-raf, e de um efeito anticáncer em um animal de sangue quente, e para o tratamento de uma doença
BR112014008686A2 (pt) derivados de oxazina e uso dos mesmos no tratamento de doença
BRPI0407504A (pt) heterociclos n-arila substituìdo, processo para sua preparação e uso dos mesmos como medicamentos
BR112015014372A8 (pt) inibidores de autotaxina, seus usos, e composição e combinação farmacêuticas".
BRPI0514365A (pt) aminas policìclicas substituìdas por arila, método para a produção destas, e uso destas como medicamento
BRPI0410760A (pt) compostos, processo para fabricação dos mesmos, composições farmacêuticas e uso deste compostos
BRPI0915064B8 (pt) derivados de quinoxalinadiona, seus usos, e medicamentos
TW200616985A (en) Salicylthiazoles substituted by diphenylamine or diphenylamine derivatives, process for their preparation and their use
BR122019010200B8 (pt) compostos de pirazol-quinazolina, seus sais, produtos ou kits e composições farmacêuticas
TW200635878A (en) Hydroxybiphenylcarboxylic acids and derivatives, processes for preparing them and their use
BRPI0513744A (pt) derivados de guanidina e usos terapêuticos dos mesmos
BRPI0615145A2 (pt) derivados de xantina como agonistas hm74a seletivos
BR112012015916A2 (pt) derivados de pirazina e seu uso no tratamento de distúrbios neurológicos
BRPI0512796A (pt) composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito inibitório de b-raf, e um efeito anticáncer em um animal de sangue quente, e para tratar uma doença
BR112012024379A2 (pt) "peptídeos glucagon, seu uso, bem como composição farmacêutica"
BR0009641A (pt) Derivados de 1,4-benzotiazepin-1,1-dióxido, substituìdos com radicais de açúcar, processo para produção dos mesmos, medicamentos contendo esses compostos e sua utilização
BRPI0607583A2 (pt) derivados de piridin-2-carboxamida como antagonistas mglur5, método para sua preparação, medicamento contendo os mesmos, bem como uso relacionado aos referidos compostos
BRPI0514679A (pt) composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito inibitório de b-raf e um efeito anticáncer em um animal de sangue quente, e para tratar uma doença ou condição
BRPI0507104A (pt) n-ciclohexilimidazolinonas substituìdas com efeito modulador de mch

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.